GV, MRL Ventures Fund and WuXi Healthcare Ventures participated in a series B round that lifted the small molecule therapy developer's overall funding to $120m.

CyberLink has reinvested in the beauty product sampling service through a series C round that was led by Goldman Sachs.

Tencent participated in the HR management software provider's series D round, which was disclosed together with $50.5m in series C funding.

IP Group was among the investors for UPenn-founded cancer immunotherapy developer Carisma Therapeutics, which has now raised nearly $109m altogether.

Sanofi Ventures contributed to a series C round for Dice Molecules, which is advancing a potential psoriasis treatment.

Livzon Pharmaceutical, Merck & Co and AbbVie helped the immuno-oncology therapy developer take its overall funding to $109m.

Taiho Ventures returned for a $72m series B round closed by Werewolf Therapeutics, which is now set to advance two lead oncology assets through phase 1 trials.

UPMC Enterprise has returned for a $72m series B round raised by Werewolf Therapeutics, which is now set to advance two lead assets through phase 1 trials.

Osage University Partners has contributed to an $80m round for Dice Molecules, which is advancing Stanford University research and is also backed by Sanofi and Alexandria.

Novo helped the cardiac pump developer CorWave secure series C funding to increase its total funding to over $95m.